A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2020-04-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Bevacizumab; Carboplatin; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gemcitabine; Nivolumab; Paclitaxel; Pemetrexed

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Histologically confirmed locally advanced or stage IV NSCLC

• Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2

• Tumor tissue sections must be available for biomarker evaluation

Exclusion Criteria:

• Untreated or active/progressing Central Nervous system (CNS) metastases

• Active, known or suspected autoimmune disease

• Known history of testing positive for HIV or AIDS

• Active or chronic infection of hepatitis B virus or hepatitis C